Alpine Immune Sciences appoints Andrew S. Sandler, M.D. as CMO

Alpine Immune Sciences, Inc., a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, has announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer.

Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler’s anticipated start date is August 17, 2022.

Stanford Peng, M.D., Ph.D., President and Head of Research and Development at Alpine, said:

“We are very excited and fortunate to have Andy join the Alpine team. His appointment comes at a time where we are quickly advancing our three development programs across multiple oncology and autoimmune disease indications.

“Andy is a highly experienced Chief Medical Officer with extensive clinical development expertise, and has a passion for developing novel therapies for patients with life-threatening and debilitating diseases.”

Dr. Sandler said:

“I am thrilled to join the Alpine team and continue to advance the clinical strategy and development of the company’s extremely promising pipeline, including acazicolcept, davoceticept, and ALPN-303.

“I look forward to integrating with the development teams to continue to advance these exciting therapies that were built from Alpine’s directed evolution platform and have the potential to improve the lives of many patients.”

Dr. Sandler brings over 25 years of industry and clinical practice experience.

Prior to his role at Kiadis Pharma/Sanofi, Dr. Sandler was Senior Vice President of Medical Affairs at Medivation (Pfizer).

Before that, he held various roles including Chief Medical Officer, Executive Vice President, Research and Development, Seattle Site Head, and Senior Vice President, Clinical and Medical Affairs at Dendreon Pharmaceuticals.

Earlier in his career, Dr. Sandler was Chief Medical Officer at Spectrum Pharmaceuticals and Vice President and Head of Global Medical Affairs for Oncology at Bayer Healthcare Pharmaceuticals.

He also previously held various positions at Berlex Oncology/Schering AG and Seattle Genetics, Inc.